Tc-99m labelled anti CD 66 antigranulocyte antibody imaging for assessment of bone marrow reserve.
Patients with metastatic disease to the bone marrow are at risk of significant hematologic toxicity, if they undergo myelotoxic chemotherapy. Tc-99m labelled Anti CD 66 monoclonal antibody imaging is a useful, noninvasive approach to the assessment of bone marrow reserve under such circumstances.
Matthies
Alexander
A
Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. alexander.matthies@ukb.uni-bonn.de
Reinhardt
M
M
Palmedo
H
H
Ezziddin
S
S
Abramowski
B
B
Kuhn
W
W
Biersack
H J
HJ
von Mallek
D
D
D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000276:immunology; D000943:Antigens, Differentiation / Q000276:immunology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001853:Bone Marrow / Q000000981:diagnostic imaging* / Q000502:physiology*; D019046:Bone Marrow Neoplasms / Q000150:complications / Q000000981:diagnostic imaging* / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D002277:Carcinoma / Q000150:complications / Q000000981:diagnostic imaging* / Q000556:secondary*; D015815:Cell Adhesion Molecules; D017024:Chemotherapy, Adjuvant; D005260:Female; D006098:Granulocytes / Q000276:immunology*; D006801:Humans; D008875:Middle Aged; D011237:Predictive Value of Tests; D016719:Radioimmunodetection / Q000379:methods; D012307:Risk Factors; D013667:Technetium
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D000970:Antineoplastic Agents; C069847:CD66 antigens; D015815:Cell Adhesion Molecules; D013667:Technetium